Clinical Trial Update: NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing imaging-based response to Radium-223 dichloride in metastatic, hormone-resistant prostate cancer; the study has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Metastases
• Castration-resistant Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

Sponsor: Stanford University | Conditions: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone | Phase 1 | Status: TERMINATED